10 November 2015

Pegasus Airlines


NEUTRAL


Current price: TRY19.50 12-mo T.Price: TRY22.50

Analyst Omer Omerbas +90 (212) 334 95 21 omer.omerbas@akyatirim.com.tr

3Q15 Earnings Comment

3Q15 Actual result vs. estimates						
<u>TRYmn</u>	<u>Actual</u>	Consen.	<u>Ak</u>			
Revenue	1,320	1,333	1,345			
EBITDA	423	383	338			
margin	32.1%	28.7%	25.2%			
Net Inc.	234	256	206			





Comment: Strong operating performance, yet net income remained below the consensus due to high derivative losses

- ✓ Pegasus recorded TRY234mn net profit in its 3Q15 financial statements, some 10% below the consensus estimate of TRY256mn but above the house call of TRY206mn. The top-line figure was in-line with the estimates (TRY1,320mn actual vs. TRY1,333mn consensus estimate and TRY1,345mn house call). The 3Q15 EBITDA margin was strong at 32.1% with a 2pp YoY expansion, by far better than the 28.7% consensus estimate (nominal EBITDA of TRY423mn beat the consensus by 18%) and 25.2% house estimates. It is worth noting that a quarter ago, the company had recorded an 11pp YoY contraction in its EBITDA margin. However high net financial expenses, driven by the TRY87mn loss recorded from the derivative contracts fully erased the operational gains and pushed the bottom-line below the consensus call.
- ✓ We would expect a positive market reaction to the good Q3 operational delivery of Pegasus Airlines, despite the miss at the bottom-line level. Pegasus shares have underperformed the benchmark index and rival THY by 20% and 16% respectively in the last 3M (since the release of the poor 2Q15 financial results). Besides the slower pax growth and steep yield contraction, the notable deterioration at the on-time performance (fell below the 60% level in August compared to 91% in 2013FY and 85% in 2014FY) had also weighed negatively on the share performance. Under the current circumstances, the pick-up in pax growth (+15.5% YoY in 3Q15 after 10% YoY in 1H15), milder yield decline reported in 3Q15 and the improvement in on-time performance (recovered to 70% in September and 80% in October) should ease part of the concerns in the investors' minds in the short term, in our view. That said, the risks on performance in the long run remain in place, particularly considering the increasing competitive threat from THY. The management will hold a conference call today to discuss the results and the outlook. After quickly reflecting the 3Q15 realizations to our model, we revised up our 2015 and 2016 EBITDA estimates by 13% and 6% respectively. Our new 12-month TP for Pegasus is TRY22.50/share (previously: TRY21.95), "Neutral" maintained.

Key Highlight: The yield contraction was milder in 3Q15 compared to 2Q15, as expected

- ✓ Pegasus' 3Q15 top-line grew 19% YoY to TRY1,320mn. Scheduled passenger revenues in TRY terms were up 21% YoY in 3Q15, accelerating from the 5% YoY growth recorded in 2Q15 the contraction in yields that hit the 2Q15 top-line was still in effect in 3Q15, but at a lesser magnitude as expected (total US\$ yield was down 17% YoY in 3Q15 compared to 25% drop in 2Q15). Still, ancillary revenues posted 19% YoY growth in EUR terms in 3Q15 (on top of the 25% growth recorded in 1H15). Charter revenues fell by 34% YoY to EUR19mn in 3Q15, maintaining the trend from the previous period. Overall, Pegasus' EUR RASK was down 6% YoY in 3Q15.
- ✓ The airline's 3Q15 EBITDA came in at TRY423mn with 23% YoY growth. Pegasus recorded 37% YoY decline in its fuel CASK in USD terms, parallel to the 45% YoY slide in the jet fuel price. The overall EUR CASK was down 8% YoY in 3Q15 (better than our estimate) following the 4% increase recorded in 1H15.

Please see penultimate page for additional important disclosures. Ak Yatirim Menkul Degerler A.S. ("AK INVESTMENT") is a foreign broker-dealer unregistered in the USA. AK INVESTMENT research is prepared by research analysts who are not registered in the USA. AK INVESTMENT research is distributed in the USA pursuant to Rule 15a-6 of the Securities Exchange Act of 1934 solely by Rosenblatt Securities Inc., an SEC registered and FINRA-member broker-dealer.

AKInvestment

Key P&L items, TRYmn	3Q15	3Q14	YoY Ch.	2Q15	QoQ chg.	9M15	9M14	YoY Chg.
Revenues	1,320	1,105	19%	834	58%	2,737	2,410	14%
Gross Profit	438	337	30%	63	597%	466	423	10%
Gross marg.	33.2%	30.5%		7.5%		17.0%	17.6%	
EBITDA	423	332	27%	34	1145%	404	384	5%
EBITDA marg.	32.1%	30.1%		4.1%		14.8%	15.9%	
Net Profit	234	251	-7%	35	562%	195	235	-17%

Key B/S & CFS items, TRYmn	3Q15	2Q15	1Q15	4Q14	3Q14
Net debt	228	322	408	497	84
FX position	1432	1091	842	811	875
OP. cash flow	262	236	116	-223	251
Free cash flow	177	173	101	-260	238

AKInvestment

DISCLAIMER

This report has been prepared by Ak Investment (Ak Yatırım Menkul Değerler A.Ş.) by using the information and data obtained from sources which are reasonably believed to be trustworthy. The statements indicated in the report should not be assumed to be sales or purchase offers under any circumstances. Ak Investment does not guarantee that the information contained is true, accurate and unchangeable. Thus, the readers are advised to have the accuracy of the information contained confirmed before acting by relying on such information and the readers shall bear the responsibility of the decisions taken by relying thereon. Ak Investment shall not in any case be responsible for incompleteness and inaccuracy of the information. Furthermore, the personnel and consultants of Ak Investment and Akbank shall not have any responsibility in any case for direct or indirect damage caused by such information. Moreover, Ak Investment shall not be held liable for any damage to the hardware or software of the receiver caused by a virus, detected transfer or any other technical reason in case of the receipt of the reports via internet or through e-mail.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by Ak Yatirim Menkul Degerler A.S. ("AK INVESTMENT"), a company authorized to engage in securities activities in Turkey. AK INVESTMENT is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Rosenblatt Securities Inc, 20 Broad Street 26th Floor, New York NY 10005, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through AK INVESTMENT. Rosenblatt Securities Inc. accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Rosenblatt Securities Inc. and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Ownership and Material Conflicts of Interest

Rosenblatt Securities Inc. or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Rosenblatt Securities Inc, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Rosenblatt Securities Inc. is not aware of any material conflict of interest as of the date of this publication

Compensation and Investment Banking Activities

Rosenblatt Securities Inc. or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

AKInvestment

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither AK INVESTMENT nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

AK INVESTMENT may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of AK INVESTMENT.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by AK INVESTMENT with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of AK INVESTMENT and AK INVESTMENT accepts no liability whatsoever for the actions of third parties in this respect.